Cortisol drives the insulin resistance and visceral fat GLP-1 is fighting
This dosing convenience, combined with robust weight loss and cardiovascular benefits, expands the addressable patient pool beyond diabetes to include obesity, heart disease, and metabolic disorders
Third, exploring personalized medicine approaches that account for genetic, epigenetic, and environmental factors influencing ferroptosis will enable the development of tailored therapies for individual patients
Patients who start with genetic insights often achieve better results faster and experience fewer dose-related side effects
This is similar to the question of using expired semaglutide , where potency is the primary concern
33,34 Head-to-head data directly comparing GLP-1 RAs in obesity remain limited